Lacramioara Ivanciu, PhD
Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)
Skip to content
BA in Biology - University of Bucharest, Bucharest, Romania
PhD in Biology - University of Bucharest, Bucharest, Romania
MS in Biology - University of Bucharest, Bucharest, Romania
Research Assistant Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Hui DJ, Edmonson SC, Podsakoff GM, Pien GC, Ivanciu Lacramioara, Camire RM, Ertl H, Mingozzi F, High KA, Basner-Tschakarjan E.: AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes. Mol Ther Methods Clin Dev. 30(2): 15029, September 2015.
Ivanciu L, Camire RM. Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity. Blood 126(1): 94-102, July 2015.
Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T, Hettinger J, Carioto M, Jiang Y, Brodsky J, Prabhala H, Zhang X, Attarwala H, Hutabarat R, Foster D, Milstein S, Charisse K, Kuchimanchi S, Maier MA, Nechev L, Kandasamy P, Kel'in AV, Nair JK, Rajeev KG, Manoharan M, Meyers R, Sorensen B, Simon AR, Dargaud Y, Negrier C, Camire RM, Akinc A.: An RNAi therapeutic antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nature Medicine 21(5): 492-7, May 2015.
Ivanciu Lacramioara, Krishnaswamy Sriram, Camire Rodney M: New insights into the spatiotemporal localization of prothrombinase in vivo. Blood 124(11): 1705-14, Sep 2014.
Pavani Giulia, Ivanciu Lacramioara, Faella Armida, Marcos-Contreras Oscar A, Margaritis Paris: The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo. Blood 124(7): 1157-65, Aug 2014.
Nabil K. Thalji, Lacramioara Ivanciu, Sriram Krishnaswamy, Rodney M. Camire: The mechanism of rivaroxaban reversal by FXa reveals a paradoxical property of direct FXa inhibitors. FASEB meeting "Proteases in Hemostasis and Vascular Biology" June 2015.
Pavani Giulia, Ivanciu Lacramioara, Faella Armida, Marcos-Contreras Oscar O, Margaritis Paris : Binding of FVIIa to the endothelial protein C receptor enhances its hemostatic function in hemophilic mice. Thrombosis and Hemostasis Summit of North America April 2014.
Pavani, Lacramioara Ivanciu, Katherine A. Stafford and Paris Margaritis: A single amino acid in the Gla domain mouse FVIIa allows its binding to the endothelial protein C receptor and enhances its coagulant activity in vivo. 57th American Society of Hematology Annual Meeting (poster) December 2015.
Ivanciu L. Modulating Factor V levels in vivo. Novo Nordisk Inc.; 2015 Jun; Copenhagen, Denmark.
2015, 2015 GRIFOLS Martin Villar Haemostasis Award, "The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo" paper
2014, Early Career Investigator Award, The Bayer Hemophilia Awards Program, Bayer Corp
2012, Martin Villar Haemostasis Award, (1st Prize)
2012, Poster Award, 22nd Children's Hospital of Philadelphia Research Poster Day
2012, 2012 GRIFOLS Martin Villar Haemostasis Award, "In vivo genome editing restores haemostasis in a mouse model of haemophilia" manuscript
2011, Travel Award, 53th Annual Meeting of American Society of Hematology
2010-2012, Recipient of the Judith Graham Pool Postdoctoral Research Fellowship, National Hemophilia Foundation
2010, Travel Award, 52th Annual Meeting of American Society of Hematology
2008-2010, Ruth L. Kirschstein National Research Service Award (T32)
2008, Travel Award, 50th Annual Meeting of American Society of Hematology
2015-present, PLOS One
2015-present, Journal of Thrombosis and Haemostasis
2011-present, International Society of Thrombosis and Haemostasis
2014-present, World Federation of Hemophilia
2013-Present North American Society on Thrombosis and Hemostasis (NASTH)
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.